|
|
||||||||||
|
J Am Coll Cardiol, 2005; 45:989-994, doi:10.1016/j.jacc.2004.11.060 © 2005 by the American College of Cardiology Foundation |

* EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China
Manuscript received September 14, 2004; revised manuscript received October 29, 2004, accepted November 2, 2004.
* Reprint requests and correspondence: Dr. Antonio Colombo, EMO Centro Cuore Columbus, 48 Via M. Buonarroti, 20145 Milan, Italy (Email: info{at}emocolumbus.it).
OBJECTIVES: The purpose of the present report was to evaluate clinical and angiographic outcomes of drug-eluting stent (DES) implantation in saphenous vein graft (SVG) lesions.
BACKGROUND: The safety and efficacy of DES implantation for the treatment SVG lesions remains uncertain.
METHODS: We evaluated in-hospital and six-month outcomes in 61 consecutive patients treated with DES in SVG lesions from March 2002 to March 2004 (DES group), as compared to 89 consecutive patients treated with bare-metal stents (BMS) in the 24 months immediately before the introduction of DES (BMS group). Major adverse cardiac events (MACE) including death, myocardial infarction, target lesion revascularization (TLR), and target vessel revascularization (TVR) were recorded in-hospital and at six-month follow-up.
RESULTS: The rate of in-hospital MACE was similar between the two groups (6.6% vs. 5.6%, p = 1.0). Cumulative MACE at six months was 11.5% in the DES group and 28.1% in the BMS group (p = 0.02). The DES group had a significantly lower incidence of in-segment restenosis (10.0% vs. 26.7%, p = 0.03), TLR (3.3% vs. 19.8%, p = 0.003), and TVR (4.9% vs. 23.1%, p = 0.003). By Cox regression analysis, diabetes (hazard ratio [HR]: 3.03; 95% confidence interval [CI]: 1.33 to 6.90; p = 0.008), usage of BMS (HR: 2.53; 95% CI: 1.07 to 5.97; p = 0.03), and age of SVG (HR: 1.10; 95% CI: 1.02 to 1.19; p = 0.02) were identified as predictors of MACE at six-month follow-up.
CONCLUSIONS: Compared to BMS implantation, DES implantation in SVG lesions appears safe with favorable and improved mid-term outcomes.
| |||||||||||||
This article has been cited by other articles:
![]() |
N Melikian and W Wijns Drug-eluting stents: a critique Heart, February 1, 2008; 94(2): 145 - 152. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wilson and J. T. Willerson Myocardial Revascularization with Percutaneous Devices Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598. [Full Text] |
||||
![]() |
G. V. Gonzalez-Stawinski and B. W. Lytle Coronary Artery Reoperations Card. Surg. Adult, January 1, 2008; 3(2008): 711 - 732. [Full Text] |
||||
![]() |
A. Colombo and A. Chieffo Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease) Circulation, September 18, 2007; 116(12): 1424 - 1432. [Full Text] [PDF] |
||||
![]() |
N. Beohar, C. J. Davidson, K. E. Kip, L. Goodreau, H. A. Vlachos, S. N. Meyers, K. H. Benzuly, J. D. Flaherty, M. J. Ricciardi, C. L. Bennett, et al. Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents JAMA, May 9, 2007; 297(18): 1992 - 2000. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Win, A. E. Caldera, K. Maresh, J. Lopez, C. S. Rihal, M. A. Parikh, J. F. Granada, S. Marulkar, D. Nassif, D. J. Cohen, et al. Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents JAMA, May 9, 2007; 297(18): 2001 - 2009. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-P. B.-L. Rocca, C. Kaiser, M. Pfisterer, and on behalf of the BASKET Investigators Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET) Eur. Heart J., March 2, 2007; 28(6): 719 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hoffmann, T. Pohl, R. Koster, R. Blindt, P. Boeckstegers, and T. Heitzer Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study Heart, March 1, 2007; 93(3): 331 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Vermeersch, P. Agostoni, S. Verheye, P. Van den Heuvel, C. Convens, N. Bruining, F. Van den Branden, and G. Van Langenhove Randomized Double-Blind Comparison of Sirolimus-Eluting Stent Versus Bare-Metal Stent Implantation in Diseased Saphenous Vein Grafts: Six-Month Angiographic, Intravascular Ultrasound, and Clinical Follow-Up of the RRISC Trial J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2423 - 2431. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1689 - 1706. [Full Text] [PDF] |
||||
![]() |
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas Highlights of the Year in JACC 2005 J. Am. Coll. Cardiol., January 3, 2006; 47(1): 184 - 202. [Full Text] [PDF] |
||||
![]() |
A. Colombo and J. Cosgrave Paclitaxel-Eluting Stents in Complex Lesions JAMA, September 14, 2005; 294(10): 1268 - 1270. [Full Text] [PDF] |
||||
![]() |
Drug-Eluting Stents in SVG Interventions Journal Watch Cardiology, May 13, 2005; 2005(513): 3 - 3. [Full Text] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |